Drugs · acquisition-cost intelligence
Avalide
irbesartan and hydrochlorothiazide· ingredient hydrochlorothiazideAngiotensin II receptor blockers (ARBs), plain· HYDROCHLOROTHIAZIDE 12.5 mg/1; IRBESARTAN 150 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; IRBESARTAN 300 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; IRBESARTAN 300 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.17972
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-10-222026-05-20
Same-ingredient options by acquisition cost
Other hydrochlorothiazide products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| hydrochlorothiazide | $0.01219 | −$0.16750 |
| hydrochlorothiazide | $0.02865 | −$0.15110 |
| hydrochlorothiazide | $0.03324 | −$0.14650 |
| hydrochlorothiazide | $0.04038 | −$0.13930 |
| Diovan HCT | $0.14221 | −$0.03750 |
| Micardis HCT | $0.36196 | +$0.18220 |
| Amiloride Hydrochloride and Hydrochlorothiazide | $0.44788 | +$0.26820 |
| spironolactone and hydrochlorothiazide | $0.53463 | +$0.35490 |
Medicare Part D coverage · CY2026
On 325 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 56% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.